Chlordecone (Kepone)

CASRN 143-50-0

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (24 pp, 231 K) last updated: 09/22/2009

RfD (mg/kg-day) System Basis PoD Composite UF Confidence
3 x10-4 Urinary Renal lesions (glomerulosclerosis) in female Wistar rats BMDL10 : 0.08
mg/kg-day
300 Medium

Reference Concentration for Inhalation Exposure (RfC) (PDF) (24 pp, 231 K) last updated: 09/22/2009
Information reviewed but value not estimated.

Cancer Assessment


Weight of Evidence for Cancer (PDF) (24 pp, 231 K) last updated: 09/22/2009

WOE Characterization Framework for WOE Characterization
Likely to be carcinogenic to humans Guidelines for Carcinogen Risk Assessment (US EPA, 2005)
Basis:
  • Under the U.S. EPA Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), chlordecone is "likely to be carcinogenic to humans" based on data from an oral cancer bioassay in rats and mice demonstrating an increase in the incidence of hepatocellular carcinomas in both sexes of both species (NCI, 1976a, b).
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (24 pp, 231 K)

Oral Slope Factor: 1 x10 1 per mg/kg-day
Drinking Water Unit Risk: 3 x10 -4 per µg/L
Extrapolation Method: Multistage-Weibull model (implemented in TOX_RISK) with linear extrapolation from the POD (BMDL10).
Tumor site(s): Hepatic
Tumor type(s): liver hepatocellular carcinoma (NCI (1976a))


Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (24 pp, 231 K)

Information reviewed but value not estimated.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.